markers, global longitudinal strain (GLS) is a recently identified strong prognostic marker in patients with AS. 12, 13 In this prospective single-center registry study, we sought to determine the relationship between a selected group of biomarkers and outcome and recovery of ventricular function in patients undergoing TAVR. The selected biomarkers encompass different key processes such as cardiac remodeling (left ventricular mass and left atrial size), ventricular function (GLS), ventricular wall stress (B-type natriuretic peptide [BNP] ), myocardial injury (hs-TnI [high-sensitivity troponin I]), inflammation (CRP), cardiac repair or oxidative stress (GDF-15), cardiac fibrosis (GAL-3), and renal function (Cys-C). The first objective of our study was to compare the level of biomarkers between patients undergoing TAVR and age-and sex-matched healthy controls. Our second objective was to identify independent physiological correlates for the different circulating biomarkers in patients undergoing TAVR. Finally, our third objective was to explore which biomarker or combination of biomarkers was more strongly associated with mortality and recovery of ventricular function in patients undergoing TAVR.
Methods
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Study Population and Design
Adult patients with severe AS undergoing TAVR at Stanford University Medical Center were included. The protocol was approved by the Institutional Review Board of Stanford University, and written consent was obtained from all subjects. Please refer to the Data Supplement for further details. In the setting of left ventricular (LV) systolic dysfunction and low-flow, low-gradient AS, the severity of AS was confirmed by low-dose dobutamine stress echocardiography. 14 Patients with previous valve replacement surgery, known active infection or cancer, on immunosuppressive therapy, or end-stage renal disease on dialysis were excluded. Healthy sex-matched controls were recruited from a previously described population-based cohort for comparison of baseline biomarker profiles. 15 The healthy controls were not followed for clinical outcomes in this study.
Biomarkers Analysis
At baseline, we measured BNP, hs-TnI, high-sensitivity CRP, and GAL-3 using Abbott architect instrument (ci4100). Roche Biochemistry analyzer was used to measure Cys-C; ELISA assay (R&D) was used for GDF-15. All samples analyzed were collected in the fasting state and frozen at −80°C at Stanford Human Immune Monitoring Core Laboratory. All biomarker analyses were performed at Abbott Core Laboratory, which was blinded to the clinical characteristics of the study.
Echocardiographic Assessment
Echocardiography was performed using commercially available echocardiographic systems (Sonos 7500, iE33, and EPIQ 7C; Philips Medical Imaging, Eindhoven, the Netherlands) and analyzed by Stanford Biomarker and Phenotypic Core Laboratory following standard protocols.
14 Further details are included in the Data Supplement. We chose 15% change in GLS as meaningful change according to the recent recommendation of the ASE and task force of strain imaging. 16 We chose a higher value of 20% for changes in LV mass and left atrial volume recognizing the greater variability in serial imaging of wall thickness and cardiac dimensions. 
Statistical Analysis
Please refer to the Data Supplement for further details. We normalized GDF-15 and BNP values using logarithmic base 10 transformation for analysis. One-way ANOVA or Kruskal-Wallis test was used for comparison of biomarkers among 3 healthy groups (young, middle, and old) and the TAVR group, and post hoc analysis was performed with Turkey-HSD (honest significant difference) multiple comparison tests or Games-Howell, as appropriate. Repeated ANOVA was used to compare echocardiographic data of left ventricular mass index (LVMI), GLS, and left atrial volume index (LAVI) at the 3 time points (baseline, 1 month, and 1 year).
Univariate and multivariate analyses were performed to determine the associates of each biomarker using covariates as age, sex, body mass index, and hemodynamic and echocardiographic parameters. Parameters with P<0.10 were selected for creating a multivariate logistic regression model using an indicator for improvement in LV function as the binary outcome separately for GLS, LVMI, and LAVI. Similarly, univariate and multivariate Cox regression tests were performed for outcome analysis. The log-rank test was performed to compare survival and shown in Kaplan-Meier plots. We also performed a partial correlation analysis to assess the correlation between each pair of biomarkers while adjusting for the other measured biomarkers.
The survival, survC1, and survIDINRI packages in R were used for survival analysis and calculation of C index, integrated discrimination improvement (IDI), and net reclassification improvement (NRI) based on the study by Uno et al. 18 The IDI is independent of category and considers separately the actual change in calculated risk for each individual. NRI illustrates the percentage of a population that is accurately reclassified, providing clinically meaningful results rather than only statistically significant differences between χ 2 and C statistic values.
Results

Baseline Characteristics
One hundred and twelve consecutive patients with severe AS who underwent TAVR and met inclusion criteria were enrolled in this study. One hundred subjects were recruited to the healthy aging cohort. Further, we divided the healthy aging group to younger (<60 years, n=34), middle (60-75 years, n=32), and an older age group (>75 years, n=32). The mean age of the TAVR cohort was 84 years, and 59% were men ( Table 1 ). The older healthy aging cohort was matched to the TAVR cohort for age and sex. Tables 1
WHAT IS KNOWN
• Mortality after transcatheter aortic valve replacement remains high.
• There is currently no specific tool to predict longterm outcome in patients undergoing transcatheter aortic valve replacement.
WHAT THE STUDY ADDS
• The addition of circulating biomarkers to clinical risk scores can significantly improve risk stratification in patients undergoing transcatheter aortic valve replacement.
• Circulating biomarkers may perform better than frailty or baseline echocardiographic parameters in improving risk stratification.
• GDF-15 (growth differentiation factor 15) level is associated with both lack of recovery in ventricular function and increased 1-year mortality in patients undergoing transcatheter aortic valve replacement. and 2 summarize the clinical and echocardiographic characteristics of enrolled patients. Transfemoral, transaortic, and transapical approaches were used in 92 (82%), 15 (13%), and 5 (5%) patients, respectively. Baseline echocardiographic examination was performed in all patients and repeated in 77 patients at 1-year after TAVR. Twenty patients (18%) died within the first year. Median follow-up was 679 days (Q1-Q3, 346-964 days) after TAVR. Table I in the Data Supplement). B, Partial correlation network analysis. Lines connecting variables represent statistically significant relationships (P<0.05). Partial correlation analysis showed GDF-15 (growth differentiation factor 15) to significantly correlate with GAL-3, CRP (C-reactive protein), BNP, and Cys-C (cystatin-C) when adjusted for the other biomarkers within the figure. A full line represents a positive relationship, whereas a dashed line represents an inverse relationship. Thicker lines indicate stronger correlation as measured by r value. Alb indicates albumin; AVAI, indexed aortic valve area; eGFR, estimated glomerular filtration rate; GAL-3, galectin-3; GLS, global longitudinal strain; hs-TnI, high-sensitivity troponin I; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; PAlb, prealbumin; and STS, the Society of Thoracic Surgeons score. Biomarkers of Cardiac Recovery and Outcome in TAVR in (1) LVMI, (2) GLS, and (3) LAVI at 1 month and 1 year after TAVR in patients. Twenty-three percent of patients presented with improved LVMI (decreased ≥ relative change of 20%), and 77% patients remained stable (−20%<relative change<20%) at 1 year, whereas 47% presented with increased GLS (increased in absolute value≥relative change of 15%), and 53% remained stable (−15%<relative change<15%).
Biomarker Profiles at Baseline
Compared with age-and sex-matched controls, patients with TAVR had significantly higher levels of 6 biomarkers (Figure 1) . Among biomarkers, there was an age-related progressive increase in the biomarker levels, more prominent for GDF-15, BNP, and Cys-C (Figure 1 ). In our healthy cohort, CRP did not increase in the different aging groups.
The correlations between baseline characteristics, echo parameters, and biomarkers are represented in Figure 2A ( Table I in the Data Supplement). The different biomarkers in the TAVR group were not independent of each other. BNP and GDF-15 correlated with each other (r=0.53; P<0.0001), and GDF-15 also correlated with GAL-3 and CRP (r=0.36; P=0.005 and r=0.26; P<0.0001, respectively). A partial correlation analysis showed GDF-15 to be correlated to GAL-3, CRP, BNP, and Cys-C, when adjusted for other biomarkers, highlighting the connectivity of GDF-15 among common biomarkers ( Figure 2B ). 
Association of Biomarkers With All-Cause Mortality
Of the biomarkers assayed, GDF-15 and CRP emerged as significantly associated with all-cause mortality on both univariate and multivariate analyses (Table 3) . Furthermore, survival analysis based on previously defined cutoffs for GDF-15 (2000 pg/mL) and CRP (2 mg/L) 19, 20 showed significantly worse survivals in subgroups with elevated biomarker levels (Figure 3 ; GDF-15, log-rank P<0.0001; CRP, log-rank P=0.01). Although not found to be independently correlated in multivariate analysis, BNP and hs-TnI also showed significant difference in survival based on predefined cutoff values of 250 pg/mL and 6 ng/L, respectively (Figure 3) . 21 ,22 GAL3 and Cys-C trended toward significance (P values 0.06 and 0.07, respectively). However, when using median values for the biomarkers, Cys-C also showed significant difference in mortality ( Figure II in ≥8] ), the elevation in GDF-15 and CRP was associated with significant increase in mortality at 1 year in both subgroups ( Figure 4A ). The C statistics for STS score alone in risk prediction of mortality improved significantly when GDF-15 and CRP were added to the risk model (0.65-0.79; P<0.05). The IDI and category-free NRI indices were also calculated for the censored survival data at 2 years using models with and without inclusion of CRP and GDF-15 to STS score. There was a significant improvement in both indices-IDI 0.19 (95% confidence interval, 0.09-0.29; P<0.001) and category-free NRI (>0) 1.06 (95% confidence interval, 0.64-1.44; P<0.001). Overall, 79% of the event group and 26% of the nonevent group were reclassified with the addition of biomarkers. In contrast, inclusion of frailty to STS score did not result in significant improvement in prediction for risk of mortality (IDI 0.01; P=0.219 and NRI 0.258; P=0.169). However, when frailty was used with GDF-15, they performed similarly compared with the model including GDF-15 and (Figure 4) . We also calculated the STS-TAVR score for each subject, which is a recently developed score to predict in-hospital mortality based on the STS/TVT Registry (http:// tools.acc.org/tavrrisk). 23 We found that GDF-15 and CRP significantly improved the C statistics of STS-TAVR score in predicting 1-year survival (0.43-0.79; P<0.0001; Figure III in the Data Supplement). Analysis of censored data using the log-rank method in these subgroups also showed that elevated biomarkers correlated with worse outcome in both the intermediate and high STS score subgroups, whereas frailty was not predictive of worse outcome in the intermediate STS score subgroup ( Figure IV in the Data Supplement).
Association of Reverse Remodeling With All-Cause Mortality
Baseline echocardiographic parameters were not associated with all-cause mortality. However, improvement in GLS at 1 month associated with better outcome in a multivariate regression analysis (Table 3 ; χ 2 P=0.01).
Association Between Baseline Biomarkers and Functional Recovery at 1 Year
We found biomarkers and baseline cardiac function to independently correlate with improvement in GLS, LVMI, and LAVI at 1 year (Table 4) . Specifically, age, baseline GLS, log GDF-15, and Cys-C together predicted improvement in GLS with area under the curve (AUC) 0.90 (P<0.0001), and baseline LVMI and GAL-3 predicted improvement in LVMI (AUC 0.79; P<0.0001) on multivariate analysis. Lower level of GDF-15 was the only significant predictor of improvement in LAVI (AUC 0.75; P=0.003).
Discussion
The main finding of our study is that GDF-15 is a centrally connected biomarker in patients undergoing TAVR and is associated with all-cause mortality and lack of recovery in ventricular function. Although baseline echocardiographic parameters were not as strongly related to outcome as circulating biomarkers, lack of improvement at 1 month in GLS emerged as a stronger correlate of outcome. GDF-15 is a stress-induced cytokine of the TGF-β (transforming growth factor-β) superfamily, which increases during tissue injury and inflammatory states. It is highly expressed in cardiomyocytes, macrophages, endothelial cells, and vascular smooth muscle cells. 24, 25 We found GDF-15 to be the most connected biomarker among the different biomarkers assayed and with ventricular function, potentially highlighting its central role in the ventricular remodeling process. The central role of GDF-15 is also highlighted by its independent correlation with survival and reverse ventricular remodeling.
Previous studies have found an age-specific increase in BNP and TnI in healthy subjects. [26] [27] [28] Here, we report that GDF-15 levels also increase with healthy aging, in addition to other cardiac biomarkers. When compared with the healthy aging cohort, all biomarkers were significantly elevated in the TAVR patients. Furthermore, as presented in our correlation matrix and partial correlation analyses, we found that the circulating and imaging biomarkers assayed were not independent of each other. BNP was closely related with baseline GLS and LVMI, whereas GDF-15 and hs-TnI were correlated with LVMI. Few studies have analyzed these correlations in patients with pressure-overloaded ventricles. Kuznetsova et al 29 found a relationship between LVH and hs-TnI in the Consistent with previous studies, we have also observed an overall improvement in LV function 1 month after TAVR, and this improvement extended out to 1 year from TAVR ( Figure  I in the Data Supplement). The response was, however, variable with some patients showing greater improvement than others. Furthermore, we found baseline biomarkers to have predictive capacity for cardiac recovery. Baseline ventricular function and GDF-15 were strong independent predictors of reverse cardiac remodeling after TAVR (AUC>0.80). Despite strong correlation of BNP with LV functional recovery after TAVR on univariate analysis, this association was no longer significant when the baseline function was included in the multivariate model. Among baseline parameters, GDF-15 was the only parameter associated with all-cause mortality and functional recovery at 1 year in survivors. GDF-15 also significantly improved the risk model when added to STS score. Although frailty has been associated with worse 1-year Figure 4 . Addition of GDF-15 (growth differentiation factor 15) and CRP (C-reactive protein) to STS score results in integrated discrimination improvement and net reclassification improvement. A, Elevated biomarkers (GDF-15>2000, CRP>2) is associated with increased all-cause mortality in both intermediate-risk and high-risk groups by STS score at 1 year. High GDF-15 (left) and elevated GDF-15 and CRP (right) are associated with significant increase in all-cause mortality. B, Presence of frailty was associated with increased mortality at 1 year in the high-risk group; however, no correlation was found in the intermediate-risk group. Frailty did not result in significant integrated discrimination improvement (IDI) and net reclassification improvement (NRI). When combined with GDF-15, frailty is associated with increased mortality. C, The empirical distribution function of the paired difference between the risk scores (on the probability scale) estimated at time=2 years using models with and without the inclusion of CRP and GDF-15 are shown). The added value of variables (ie, IDI) is proportional to the shaded area. The vertical difference at s=0 (between the 2 black dots, where s scales the graphic between −1 and +1) is ½ NRI(>0), and the horizontal difference (between the 2 gray dots) equals the median risk score difference. y axis, cumulative probability; x axis s, difference between 2 model risk scores.
outcome in TAVR patients in a previous study, 31 we found that frailty alone did not perform as well as the biomarkers and did not significantly improve net reclassification when added to STS score in our cohort. The difference in the risk classification was especially pronounced in subjects with STS<8 in our cohort. Given the rapidly increasing number of patients with low-to-intermediate STS scores that are receiving TAVR, the clinical relevance of these findings is significant.
Among echocardiographic parameters, we found lack of improvement in GLS at 1 month to be predictive of worse outcome. Despite the association of baseline GLS and LVMI with cardiac recovery, these echo parameters did not predict all-cause mortality in multivariable models. These findings are consistent with recent reports showing biomarkers and early ventricular recovery after TAVR to predict improved survival. [6] [7] [8] 32 To the best of our knowledge, this is the first study to investigate the association between selected cardiovascular and inflammatory biomarker panels and reverse remodeling in patients undergoing TAVR. We also present a unique comparison of biomarker profiles in healthy cohort with TAVR group. The strong predictive capacity of GDF-15 and CRP together for adverse outcome reiterates the role of inflammation in AS-induced ventricular remodeling. In terms of clinical implications, this study suggests that the current risk prediction model for patients undergoing TAVR leaves significant margin for improvement and that it would be possible to improve risk stratification by inclusion of limited number of biomarkers.
There are limitations to this study. First, the study is small in size and without a validation cohort, and hence, the findings from this study are exploratory and need further studies for validation. However, our findings do validate recent studies highlighting the role of GDF-15. Future studies would include whether a combined clinical and biomarker risk score can prospectively improve the net reclassification of patient risk groups and outcomes. Measuring the dynamic changes in biomarker after TAVR may also answer the question of whether the TAVR procedure is restorative of the inflammatory process that occurs in the ventricle exposed to the large afterloads.
Conclusions
We found circulating biomarkers to have superior prognostic properties than baseline echocardiographic parameters for allcause mortality in patients undergoing TAVR. Higher level of GDF-15 predicted both poor ventricular recovery and worse survival after TAVR and improved risk prediction when added to STS score. Overall, our data suggest that an inflammatory process is important in predicting ventricular recovery and outcome in patients receiving TAVR. These markers should be validated in larger cohorts. GDF-15 , CRP, hs-TnI, GAL-3, and Cys-C). The values of OR and 95% CI were standardized by SD. AUC indicates ; BNP indicates B-type natriuretic peptide; CI, confidence interval; CRP, C-reactive protein; Cys-C, cystatin-C; GAL-3, galectin-3; GDF-15, growth differentiation factor 15; GLS, global longitudinal strain; hs-TnI, high-sensitivity troponin I; LAVI, left atrial volume index; LV, left ventricular; LVMI, left ventricular mass index; and OR, odds ratio.
